A new once-daily, fixed-dose eye drop–Rocklatan (combination netarsudil and latanoprost)–has shown efficacy in treating open-angle glaucoma and ocular hypertension. The results come from the 3-month randomized, double-masked MERCURY 1 trial.

The trial compared Rocklatan’s efficacy against monotherapy with netarsudil or latanoprost alone in adult patients with primary open-angle glaucoma or ocular hypertension.

Netarsudil may lower intraocular pressure (IOP) through increasing trabecular outflow, decreasing…

View Conference Coverage

Take a look at some of our conference coverage, visit our roundup section.

Conference Roundup

  1. Mar 19, 2019

AAO: Variation in Prostaglandin Analog Prices Analyzed

Providers don't usually ask what type of Medicare Part D plan their patients with glaucoma have but it's something that should be considered, according to Aaron Priluck, BSE, of the Department of Ophthalmology and Visual Sciences at the Truhlsen…

Journal Scan

  1. Jul 06, 2019

Real-World Data Shows Visual Field Loss Occurs Faster in Glaucoma Patients With Uveitis

Due to the widespread use of electronic medical records (EMRs), it is now possible to easily collect information from large-scale patient populations to better understand disease progression and treatment response. A new study in the American Journal of Ophthalmology is the first to use…